Business Wire

PA-GROVARA

24.3.2021 17:08:09 CET | Business Wire | Press release

Share
Grovara Raises $5.5 Million Seed Round to Transform Global Commerce with First B2B Global Marketplace for U.S. Healthy Brands

Grovara, the largest B2B global marketplace for U.S. natural and organic brands, announced today the closing of a $5.5 million seed round financing to transform global commerce. David Pottruck led the round and was named Executive Chairman, and he was joined by SPINS, Bluestein Ventures, Spiral Sun Ventures, Siddhi Capital, CEAS Investments, and E and A Venture Capital LLC.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005746/en/

The new investment will be used to expand sales and support resources in key regions worldwide and appoint leadership for brands, sales, and business development. Grovara will also invest in additional supply chain team members, roll out marketing initiatives, develop global partnerships, and continue with product enhancements to its first-to-market technology platform.

“We are happy to be joined by new investors and continue with some long-term partners who have helped us get to this point,” says Grovara Co-Founder and now CEO Abu Kamara, who previously served as Grovara’s President. “Grovara is transforming global commerce for U.S. consumer brands with the first B2B global marketplace for U.S. natural and organic brands. When you lower barriers and simplify exporting to a marketplace, you create tremendous opportunities for brands and retailers to grow their business. It's a game-changer.”

The bridge round comes at a time when the natural and organic food and beverage market and B2B ecommerce are surging. The global natural & organic products market is worth $327B with U.S. brands accounting for $110B, while a recent study of global B2B buyers found 87% of them are purchasing from online marketplaces .

“For as challenging as the last year has been, it has greatly accelerated wellness and digital transformation. Our online B2B global marketplace is positioned perfectly to shepherd this growth and put the healthiest, highest-quality products in front of more retailers who previously did not have access,” says Grovara Co-Founder Peter Groverman, who stepped away from his CEO role to fill the newly created Chief Innovation Officer position. “With this funding round, we can accelerate the onboarding of brands and buyers in our ecosystem to discover, connect and grow their international business.”

In 2020, Grovara launched its technology platform and despite the disruption related to the coronavirus pandemic, continued to grow its portfolio. In 2021, the company anticipates onboarding 200 new brands and 350 additional retailers.

Grovara’s platform, built on a decade of exporting experience, brings access, visibility, and transparency to both brands and buyers via pricing, brand and market insights, and a modern B2C user experience for B2B business.

Nine out of 10 U.S. wellness brands do not export their products, primarily due to the complexities and risks of international business. Grovara’s technology platform is built to manage the export lifecycle and provide wellness-focused, insights-driven data that accelerates growth and scale. Grovara connects major U.S. natural and organic brands like GT’s Living Foods , Wholesome Sweeteners , Honey Stinger , True Citrus , and That’s It with key global retailers like Walmart Mexico , Cencosud , Whole Foods U.K. , and Costco Taiwan .

“My career has been focused on transformational technology and how consumers and businesses use it to create better outcomes,” says Pottruck, former CEO of Charles Schwab. “It’s easy to see how Grovara is well-positioned for this moment with the best technology, the most authority, and industry-leading partners.”

Grovara was recently named a finalist for the Philadelphia Alliance for Capital and Technology (PACT) Enterprise Awards , to be held on June 28, in the Technology Startup category.

ABOUT GROVARA : Grovara is the first B2B global marketplace for natural and organic brands. Grovara increases access to wellness products for global consumers with its proprietary technology platform that connects the most promising U.S. healthy consumer brands with vetted global retailers. With only 1 in 10 wellness brands selling overseas, Grovara enables exporting with visibility, transparency and an intuitive user experience, creating a pathway for dynamic growth potential for American manufacturers and added value for worldwide retailers. More information on Grovara’s market-leading processes and partners can be found at www.grovara.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release

Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we

Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 12:18:00 CEST | Press release

An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes. Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified p

Zoomtopia: Zoom lancerer nye AI-funktioner22.10.2026 12:13:00 CEST | Pressemeddelelse

Zoom vil forkorte vejen fra mødebeslutning til udført arbejde. På konferencen Zoomtopia præsenterer virksomheden Unified Context Layer – et fælles informationslag, der forbinder samtaler, dokumenter og data, så AI kan forstå sammenhængen og hjælpe med de næste skridt. Samtidig lanceres flere nye AI-produkter og -funktioner, der skal gøre det lettere at omsætte diskussioner og beslutninger til handling. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261021318859/da/ I møder og samtaler træffes vigtige beslutninger, og virksomheder får værdifuld indsigt i deres kunder. En kundedialog kan begynde i et møde, fortsætte i telefonen og derefter gå over i en chat. Når informationen spredes mellem forskellige værktøjer, bliver det svært for både medarbejdere og AI-agenter at få et samlet billede af, hvad der er blevet sagt og besluttet. Resultatet er, at værdifuld tid går med at finde ud af, hvad der er blevet sagt og besluttet, og

TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release

Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye